Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€71.62

€71.62

1.040%
0.74
1.040%
-
 
15:37 / Tradegate WKN: A3ETYB / Name: Sandoz Group / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Sandoz Group AG Stock

There is an upward development for Sandoz Group AG compared to yesterday, with an increase of €0.74 (1.040%).

Pros and Cons of Sandoz Group AG in the next few years

Pros
?
M***** P*******
?
B****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

News

Sandoz marks 80 years of antibiotics with call for urgent political action to safeguard European medicine security
Sandoz marks 80 years of antibiotics with call for urgent political action to safeguard European medicine security
Sandoz marks 80 years of antibiotics with call for urgent political action to safeguard European medicine security
Sandoz confirms European Commission approval for biosimilars Bysumlog® (insulin lispro) and Dazparda® (insulin aspart), strengthening position in diabetes
Sandoz confirms European Commission approval for biosimilars Bysumlog® (insulin lispro) and Dazparda® (insulin aspart), strengthening position in diabetes
Sandoz confirms European Commission approval for biosimilars Bysumlog® (insulin lispro) and Dazparda® (insulin aspart), strengthening position in diabetes
Sandoz reports strong biosimilars growth in Q1 2026; full-year 2026 guidance confirmed
Sandoz reports strong biosimilars growth in Q1 2026; full-year 2026 guidance confirmed
Sandoz reports strong biosimilars growth in Q1 2026; full-year 2026 guidance confirmed